[Molecular diagnosis and response prediction to anti-tyrosine kinase receptors in oncology]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Tyrosine kinase receptors are key regulators of cell growth and proliferation, often dysregulated in cancer.
• Targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, aim to block these receptors for antitumor effects.
• Human Epidermal Growth Factor Receptors (HERs) are a significant family of tyrosine kinase receptors targeted in cancer therapy.

Purpose of the Study:

• To review the role of tyrosine kinase receptors in oncogenesis.
• To discuss current targeted therapy strategies against Human Epidermal Growth Factor Receptors (HERs).
• To highlight the need for improved diagnostic and predictive molecular markers for targeted HER-directed therapies.

Main Methods:

• Literature review of tyrosine kinase receptor signaling and targeted therapies.
• Analysis of therapeutic approaches targeting Human Epidermal Growth Factor Receptors (HERs).
• Discussion of current limitations and future directions in personalized cancer treatment.

Main Results:

• Tyrosine kinase receptor inhibition can impair cancer cell signaling and promote antitumor activity.
• Targeted therapies against HERs are under extensive investigation.
• Current therapeutic efficacy is dependent on detecting receptor expression, but this is insufficient.

Conclusions:

• Targeted therapies offer a promising avenue for cancer treatment by inhibiting key signaling pathways.
• The clinical application of HER-targeted therapies requires more sophisticated diagnostic and predictive markers.
• Development of novel molecular markers is essential for optimizing treatment selection and predicting response to HER-targeted agents.